Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Damora Therapeutics, Inc. (DMRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.25, with a market capitalisation of $1.75B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.50 to $34.89. This page covers its latest market performance, valuation, price trends and company information.
$1.75B | |
$25.25 | |
$34.89 | |
$16.50 | |
$24.75 | |
249.00 | |
594.38K | |
-- | |
$34.89 | |
$16.50 | |
-- | |
-- |
Damora Therapeutics, Inc. (DMRA) is trading at $25.25 in pre-market trading as of 2026-09-16 10:00:00, up 2.02% ($0.50) from the previous close of $24.75
Pre-market trading shows how investors are pricing DMRA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Damora Therapeutics, Inc. (DMRA) moved from $30.06 to $25.25, representing a decline of 16.00% ($4.81).
The stock traded between $24.14 and $30.74 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 653.01 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 47.6%
DMRA is currently trading at $25.25, placing it 47.6% of the way from its 52-week low of $16.50 to its 52-week high of $34.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Damora Therapeutics, Inc. (DMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.